Moreover, genetic and pharmacologic inhibition of CCR2 reduces the presence of these CD45+, CD11b+, Ly6Chi, Ly6G- cells in the TME, promotes sequestration of the cells in the bone marrow, and unmasks an effect of an immune checkpoint inhibitor to slow glioma progression (28). This evidence concerns the gene PTPRC and glioma.